Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult p...
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis...
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment....
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Hypotheses 1a and 1b: Compared to Supportive Conversation arm, the EMPOWER intervention will significantly decrease surrogate decision makers' symptoms of grief and Post Traumatic Stress Disorder (PTS...
Confirmation of Diet as a Treatment for Gulf War Illness
This clinical trial aims to confirm previous findings from a smaller study which demonstrated significant improvements in all symptoms among veterans with Gulf War Illness after one month on the dieta...
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...
Ca-Mg Butyrate in GWI
The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the phy...
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every ...
VIBRANT: VIB4920 for Active Lupus Nephritis
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in parti...
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less...
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with ac...
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis...
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys....
Top Cities for Lupus Nephritis Clinical Trials
Lupus Nephritis clinical trials are recruiting across 58 cities. Here are the cities with the most active studies:
About Lupus Nephritis
Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus, occurring in up to 60% of SLE patients. It can lead to kidney failure if untreated. Treatment includes immunosuppressive medications such as mycophenolate, cyclophosphamide, and newer agents like voclosporin.
Clinical trials are advancing new treatments for lupus nephritis. Currently, 13 studies are recruiting a combined 1,927 participants across the United States. Research is being conducted by 11 organizations including Novartis Pharmaceuticals, AstraZeneca, Weill Medical College of Cornell University and 8 others.
2026 Lupus Nephritis Research Landscape
As of March 2026, the lupus nephritis clinical trial landscape includes 13 actively recruiting studies across 58 cities in the United States. These studies are collectively seeking 1,927 participants, with an average enrollment target of 148 per study.
Research is being led by 11 different organizations, including Novartis Pharmaceuticals, AstraZeneca, Weill Medical College of Cornell University, American University, VA Office of Research and Development, and 6 others. The large number of sponsors reflects significant research interest and investment in lupus nephritis treatment advancement.
Geographically, lupus nephritis trials are most concentrated in San Francisco, California (6 trials); Los Angeles, California (5 trials); Chicago, Illinois (5 trials); Miami, Florida (4 trials); Aurora, Colorado (4 trials) and 7 other cities.
Featured Lupus Nephritis Studies
Highlighted recruiting studies for lupus nephritis, selected by enrollment size and research scope.
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Frequently Asked Questions About Lupus Nephritis Clinical Trials
Are there lupus nephritis clinical trials near me?
Yes, there are 13 lupus nephritis clinical trials currently recruiting across 58+ cities in the United States, including San Francisco, California; Los Angeles, California; Chicago, Illinois. Browse the studies above to find one at a location convenient for you.
How do I join a lupus nephritis clinical trial?
To join a lupus nephritis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are lupus nephritis clinical trials free?
Yes, participation in lupus nephritis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of lupus nephritis treatments are being studied?
Current lupus nephritis clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 11 research organizations.
Is it safe to participate in lupus nephritis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov